Elena V. Saifullina

Elena V. Saifullina

Auto-generated profile, based on publicly available information

Elena V. Saifullina


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
TKTatiana Krylova
Tatiana Krylova
YIYulia Itkis
Yulia Itkis
PTPolina Tsygankova
Polina Tsygankova
D(Denis V. Chistol (Kistol)
Denis V. Chistol (Kistol)
Konstantin LyamzaevKonstantin Lyamzaev
Konstantin Lyamzaev
EZEKATERINA ZAKHAROVA
EKATERINA ZAKHAROVA
The m.13513G>A (p.Asp393Asn) substitution in the MT-ND5 (Mitochondrially Encoded NADH/Ubiquinone Oxidoreductase Core Subunit 5) gene is a common pathogenic variant associated with primary mitochondrial disorders. It frequently causes Leigh syndrome and mitochondrial encephalomyopathy with lactate acidosis and stroke-like episodes (MELAS). In this study, we present clinical data, heteroplasmy levels in various tissues (blood, urine, and skin fibroblasts), and bioenergetic characteristics from a cohort of 20 unrelated patients carrying the m.13513G>A mutation, classified according to the following phenotypes: Leigh syndrome (n = 12), MELAS (n = 2), and Leber’s hereditary optic neuropathy (LHON, n = 6). We observed a significant correlation between high respiratory ratios and heteroplasmy levels in fibroblast cell lines of the patients. Furthermore, fibroblast cell lines with heteroplasmy levels exceeding 55% exhibited markedly reduced mitochondrial membrane potential. These findings contribute to a better understanding of the clinical and bioenergetic profiles of patients with m.13513G>A-variant-related phenotypes across different heteroplasmy levels, based on data from a single genetic center. Our data suggest that even a slight shift in heteroplasmy can improve cellular function and, consequently, the patients’ phenotype, providing a solid foundation for the development of future gene therapies for mtDNA diseases.

25 June 2020 in Annals of Clinical and Experimental Neurology
Verified
Journal Article
Open access
PDF file
ESElena V. Saifullina
Elena V. Saifullina
RMRim V. Magzhanov
Rim V. Magzhanov
ADAnzhelika I. Davletova
Anzhelika I. Davletova
AMAl’bIna K. Mardanova
Al’bIna K. Mardanova
ETEkaterina A. Timofeyeva
Ekaterina A. Timofeyeva
EZEkaterina Yu. Zakharova
Ekaterina Yu. Zakharova
Glutaric aciduria type I is an autosomal recessive disease caused by mutations in the GCDH gene, which encodes the glutaryl-CoA-dehydrogenase enzyme. A lack of this enzyme leads to the accumulation of glutaric and 3-OH-glutaric (3-hydroxyglutaric) acids in biological fluids and tissues, which have a neurotoxic effect primarily on subcortical brain structures. We present two clinical cases of glutaric aciduria type I in children diagnosed after developing neurological symptoms. One patient had acute disease onset in the form of an encephalopathic crisis, which is typical for most clinical cases of the disease. The other patient developed subacute symptoms. Generalized dystonic hyperkinesia was a key sign of the disease in both patients. Information from the medical history and clinical presentation, together with the neuroimaging results, enabled us to suspect the right diagnosis and to confirm it using biochemical and then molecular genetic tests. In both cases, despite diet therapy using a specialized medicinal product, the patients continued to have motor disturbances.

21 July 2024 in Genes
Verified
Journal Article
Open access
PDF file
MAMaria Akhkiamova
Maria Akhkiamova
Aleksander V. PolyakovAleksander V. Polyakov
Aleksander V. Polyakov
AMAndrey Marakhonov
Andrey Marakhonov
SVSergey Voronin
Sergey Voronin
ESElena Saifullina
Elena Saifullina
Olga ShchaginaOlga Shchagina
Olga Shchagina
During the expanded neonatal screening program conducted in 2023, we analyzed samples obtained from 1,227,130 out of 1,256,187 newborns in the Russian Federation in order to detect 5q spinal muscular atrophy (5q SMA). Within the 253-sample risk group formed based on the results of the first screening stage, 5 samples showed a discrepancy between the examination results obtained via various screening methods and quantitative MLPA (used as reference). The discrepancy between the results was caused by the presence of either a c.835-18C>T intronic variant or a c.842G>C p.(Arg281Thr) missense variant in the SMN1 gene, both of which are located in the region complementary to the sequences of annealing probes for ligation and real-time PCR. Three newborns had the c.835-18C>T variant in a compound heterozygous state with a deletion of exons 7–8 of the SMN1 gene, one newborn with two copies of the SMN1 gene had the same variant in a heterozygous state, and one newborn had both variants—c.835-18C>T and c.842G>C p.(Arg281Thr)—in a compound heterozygous state. Additional examination was carried out for these variants, involving segregation analysis in families, carriage analysis in population cohorts, and RNA analysis. Based on the obtained results, according to the ACMG criteria, the c.835-18C>T intronic variant should be classified as likely benign, and the c.842G>C p.(Arg281Thr) missense substitution as a variant of uncertain clinical significance. All five probands are under dynamic monitoring. No 5q SMA symptoms were detected in these newborns neonatally or during a 1-year follow-up period.

1 January 2017 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Open access
PDF file
ESE. V. Saifullina
E. V. Saifullina
RMR. V. Magzhanov
R. V. Magzhanov
IKI. M. Khidiyatova
I. M. Khidiyatova
EKE. K. Khusnutdinova
E. K. Khusnutdinova
Medical article медицинская статья

18 January 2026 in Problems of Endocrinology
Verified
Journal Article
Open access
OMO. A. Malievskiy
O. A. Malievskiy
RMR. I. Malievskaya
R. I. Malievskaya
ESE. V. Saifullina
E. V. Saifullina
Congenital hypogonadotropic hypogonadism (СНH) is a group of diseases caused by impaired synthesis or secretion of gonadotropin-releasing hormone (GnRH) and gonadotropin hormones. At present, more than twenty genes involved in the development of СНН have been described. In the structure of HGH, the most common forms of the disease are caused by pathogenic variants in genes involved in the ontogenesis, migration and survival of GnRH neurons, whereas pathology of genes involved in the action/transmission of GnRH signals in normally developed GnRH neurons is less common. This article describes a rare variant of СНН as a result of pathogenic variants in the POLR3B gene, occurring in 1.1% of cases of СНН, which is a component of hypomyelinating leukodystrophy 4H and includes hypomyelination, CHН, hypodontia. Identification of the genetic nature of the disease in this patient made it possible not only to establish the cause of CНН, but also to diagnose comorbid conditions.

7 May 2017 in Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
ESE. V. Saifullina
E. V. Saifullina
RMR. V. Magzhanov
R. V. Magzhanov
IKI. M. Khidiiatova
I. M. Khidiiatova
EKE. K. Khusnutdinova
E. K. Khusnutdinova
Background. Hereditary motor and sensory neuropathies (HMSN, Charcot–Marie–Tooth disease) form genetically heterogenous and clinically polymorphic group of diseases which predominantly affect peripheral nervous system. Correct primary diagnostics of these diseases is a starting point for planning subsequent molecular and genetic diagnostics.Objective. Analysis of primary diagnostics of HMSN for subsequent improvement of specialized medical and genetic help for patients and their families.Materials and methods. We analyzed 260 primary diagnoses of patients referred to a neurogeneticist for consultation and registered in the Genetics Consultation Clinic with the diagnosis of HMSN between 1970 and 2016.Results. A total of 17 variants of referral diagnoses of patients with HMSN were identified. They can be divided into 3 subgroups: hereditary diseases of the nervous and neuromuscular systems, other diseases of the nervous system, diseases of other systems. A correct diagnosis was listed in a little more than half (58.1 %) of all cases of primary referrals. The most common (10.8 %) erroneous referral diagnosis of patients with HMSN was Friedreich’s ataxia. Most of erroneous referral diagnoses could be confidently ruled out at the stage of primary clinical diagnosis and after electroneuromyography. Altogether, in the observed period percentage of correct referral diagnoses increased while the specter of erroneous diagnoses decreased significantly which attests to increased doctors’ awareness of HMSN.Conclusion. In order to improve HMSN diagnostics doctors should pay more attention to analysis of family medical history and perform a clinical examination of all proband’s available relatives.